Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
TritiumH3
TritiumH3 Apr. 21 at 9:18 PM
$AFMD back on track
1 · Reply
Think_Bigly
Think_Bigly Apr. 18 at 10:55 PM
$AFMD Reverse merger here: $75 to $100M
1 · Reply
deathknight
deathknight Apr. 14 at 1:31 AM
$AFMD ever seen a broke company's senior VP attending conferences and delivering keynote speeches on the behalf of the company? Me neither. But Affimed's clinical VP Bruker just did this. Very curious about this "eye opening session" regarding securing funds for clinical trials.
3 · Reply
Hodl707
Hodl707 Mar. 25 at 3:52 PM
$AFMD if we are going to hear anything it’s going to happen soon cell therapy is about to gobthrubthe roof it the next biggest thing up in biotech !!
0 · Reply
Hodl707
Hodl707 Mar. 23 at 1:17 PM
$AFMD if the website has gone to maintenance and then parked at daddy then back to maintenance this definitely a huge signal stay tuned folks !!!
1 · Reply
Think_Bigly
Think_Bigly Mar. 23 at 12:39 AM
$AFMD
1 · Reply
Hodl707
Hodl707 Mar. 21 at 3:22 AM
$AFMD Gilde already knew: ∙ The IP was going to transfer to the N.V. ✓ ∙ Roche was going to keep running trials ✓ ∙ Nature Medicine was going to publish ✓ ∙ AFM28 was going to show 40% CR at ASH ✓ ∙ The RMAT designation was going to survive ✓ ∙ The platform was going to emerge clean on the other side ✓ They knew all of that before anyone else did.
1 · Reply
Hodl707
Hodl707 Mar. 20 at 11:21 PM
$AFMD sussane speiler !!! If in fact there’s a fee settlement!!! That means what ?? Anyone ??
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:57 PM
$AFMD so anything about this March 16 court doc !!
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:25 AM
$AFMD Gilde’s LPs didn’t just give them €740 million to make money. They gave them €740 million to change medicine. Letting Affimed’s platform die in a $4.5M fire sale to MD Anderson would be a betrayal of every LP commitment Gilde made when they raised Fund VI. They cannot let this die. Their fund mandate won’t allow it. Their LP relationships depend on it. Their reputation as Europe’s premier healthcare impact investor is built on it.
0 · Reply
Latest News on AFMD
No data available.
TritiumH3
TritiumH3 Apr. 21 at 9:18 PM
$AFMD back on track
1 · Reply
Think_Bigly
Think_Bigly Apr. 18 at 10:55 PM
$AFMD Reverse merger here: $75 to $100M
1 · Reply
deathknight
deathknight Apr. 14 at 1:31 AM
$AFMD ever seen a broke company's senior VP attending conferences and delivering keynote speeches on the behalf of the company? Me neither. But Affimed's clinical VP Bruker just did this. Very curious about this "eye opening session" regarding securing funds for clinical trials.
3 · Reply
Hodl707
Hodl707 Mar. 25 at 3:52 PM
$AFMD if we are going to hear anything it’s going to happen soon cell therapy is about to gobthrubthe roof it the next biggest thing up in biotech !!
0 · Reply
Hodl707
Hodl707 Mar. 23 at 1:17 PM
$AFMD if the website has gone to maintenance and then parked at daddy then back to maintenance this definitely a huge signal stay tuned folks !!!
1 · Reply
Think_Bigly
Think_Bigly Mar. 23 at 12:39 AM
$AFMD
1 · Reply
Hodl707
Hodl707 Mar. 21 at 3:22 AM
$AFMD Gilde already knew: ∙ The IP was going to transfer to the N.V. ✓ ∙ Roche was going to keep running trials ✓ ∙ Nature Medicine was going to publish ✓ ∙ AFM28 was going to show 40% CR at ASH ✓ ∙ The RMAT designation was going to survive ✓ ∙ The platform was going to emerge clean on the other side ✓ They knew all of that before anyone else did.
1 · Reply
Hodl707
Hodl707 Mar. 20 at 11:21 PM
$AFMD sussane speiler !!! If in fact there’s a fee settlement!!! That means what ?? Anyone ??
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:57 PM
$AFMD so anything about this March 16 court doc !!
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:25 AM
$AFMD Gilde’s LPs didn’t just give them €740 million to make money. They gave them €740 million to change medicine. Letting Affimed’s platform die in a $4.5M fire sale to MD Anderson would be a betrayal of every LP commitment Gilde made when they raised Fund VI. They cannot let this die. Their fund mandate won’t allow it. Their LP relationships depend on it. Their reputation as Europe’s premier healthcare impact investor is built on it.
0 · Reply
Hodl707
Hodl707 Mar. 19 at 5:06 PM
$AFMD bootstrap inherited Affimed a debt it wasn’t a original creditor!!
0 · Reply
Hodl707
Hodl707 Mar. 19 at 3:36 PM
$AFMD Kirkland & Ellis is officially advising Affimed on the German insolvency.
1 · Reply
Hodl707
Hodl707 Mar. 19 at 5:38 AM
$AFMD  Kirkland & Ellis !!!!!! What dis mean to any one !!
0 · Reply
Hodl707
Hodl707 Mar. 18 at 11:40 PM
$AFMD Think about this for sec!! Let me know what you tjink ! MD Anderson being on that list wasn’t them trying to grab it. It was them having a seat at the table to make sure it went somewhere the science could survive.
0 · Reply
Hodl707
Hodl707 Mar. 17 at 5:54 PM
$AFMD is it over and done we at 0 !!!
2 · Reply
Hodl707
Hodl707 Mar. 11 at 10:49 AM
$AFMD If you’re Gilde, sitting on Affimed’s RMAT-designated NK cell IP, waiting to house it in Catalym — why would you rush a transaction under the most hostile FDA biologics regulator in recent memory? You wouldn’t. You’d wait. And now Prasad is gone. The regulatory environment just got materially friendlier for exactly this type of novel biologic platform.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:59 PM
$AFMD - This is particularly important for R/R HL patients, especially those who are double-refractory, as there are currently no approved therapies for this group.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:55 PM
$AFMD I still believe Gilde is in control of the float.. and paying minimal operating costs in order to maintain key trials. Why? The probability of $B FCF is very high. - Key Implications of RMAT The RMAT designation is a significant regulatory milestone that provides several benefits to accelerate the therapy's development: Enhanced FDA Interaction: It allows for more frequent and earlier meetings with the FDA to discuss development plans and potential surrogate endpoints. Expedited Pathways: It opens the door for potential accelerated approval and priority review of a future Biologics License Application (BLA)... contd..
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:34 PM
$AFMD ... Roche contd.. - The partnership continues to explore other candidates, including AFM24, a tetravalent bispecific engaging NK cells, in combination with Roche’s Tecentriq (atezolizumab), with a Phase 1/2a trial ongoing. Thus, while specific assets have been discontinued, the overall alliance between Roche and Affimed is still operational.
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:32 PM
$AFMD from Brave AI .. -Roche has not terminated its partnership with Affimed, but it has discontinued certain development programs under their collaboration. In July 2021, Roche announced the discontinuation of RG6296 (AFM26), a bispecific antibody targeting BCMA for multiple myeloma, developed under the Affimed collaboration. This decision was driven by intense competition in the BCMA space, with advanced CAR-T therapies and other bispecifics demonstrating strong efficacy. Despite Affimed’s promising NK cell-engaging platform, the project was halted due to the high bar for differentiation in this therapeutic area. Roche also discontinued two gene therapy programs licensed from 4D Molecular (4D-110 and 4D-125) due to a "change in risk-benefit profile," which affected the broader ophthalmology gene therapy landscape. However, the core strategic collaboration between Roche (via Genentech) and Affimed remains active.
0 · Reply
Hodl707
Hodl707 Mar. 6 at 5:09 AM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Mar. 6 at 2:28 AM
$AFMD I still think Gilde bought the sh*t out of this 5/16 - 5/19 of 2025.
1 · Reply